Logo

Rosetta and Admera OncoGxSelect Diagnostics Panel

Aug 04, 2016

Rosetta Genomics and Admera Health have jointly launched OncoGxSelect diagnostics panel, a next-generation sequencing-based test that detects somatic mutations and provides actionable results. The new panel uses Admera Health's industry leading NGS technology and looks at 12 genes — ALK, BRAF, EGFR, ERBB2, KIT, KRAS, MAP2K1, MET, NRAS, PIK3CA, RET, and ROS1 — commonly associated with lung cancer. It is a significant upgrade from the OncoGxLung, since it increase the number of genes examined from 5 to 12, and has the capacity to be used to diagnose other tumor types, Rosetta said. The test is a result of the 2014 marketing deal between Rosetta and Admera.

Breaking News
The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.